Shilpa Medicare Limited (NSE:SHILPAMED)
India · Delayed Price · Currency is INR | Market Cap | 80.90B |
| Revenue (ttm) | 13.15B |
| Net Income (ttm) | 1.11B |
| Shares Out | n/a |
| EPS (ttm) | 11.36 |
| PE Ratio | 72.81 |
| Forward PE | 33.56 |
| Dividend | 1.00 (0.12%) |
| Ex-Dividend Date | Sep 17, 2025 |
| Volume | 90,322 |
| Average Volume | 61,008 |
| Open | 838.95 |
| Previous Close | 836.65 |
| Day's Range | 824.75 - 841.15 |
| 52-Week Range | 555.00 - 1,000.00 |
| Beta | 0.14 |
| RSI | 41.57 |
| Earnings Date | Aug 11, 2025 |
About Shilpa Medicare
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clo... [Read more]
Financial Performance
In 2024, Shilpa Medicare's revenue was 12.88 billion, an increase of 11.69% compared to the previous year's 11.53 billion. Earnings were 782.93 million, an increase of 145.63%.
Financial StatementsNews
Shilpa Medicare jumps another 2.5% as stock extends rally on Saudi JV announcement
Shares of Shilpa Medicare surged another 2.5% in Wednesday’s session, taking their two-day rally to over 5%, after the company announced plans to set up a new joint venture in Saudi Arabia with Pharma...
Shilpa Medicare shares jump 2% after its subsidiary forms JV with Saudi Pharma giant PPI
Shilpa Medicare shares surged over 2% in early morning trade after the pharmaceutical giant announced a major step toward expanding its international presence with a new joint venture in Saudi Arabia....
Shilpa Medicare subsidiary forms strategic JV with Saudi Pharma giant PPI
Shilpa Medicare has taken a significant step toward expanding its global footprint with a new joint venture in Saudi Arabia. The pharmaceutical powerhouse has partnered with Pharmaceutical Industries ...
Shilpa Medicare Q1 Results: Revenue rises 9.9% to Rs 321 crore, Net profit jumps over 3x YoY
Shilpa Medicare Ltd. reported a sharp jump in profitability for the quarter ended June 30, 2025, with consolidated net profit surging to ₹46.89 crore, up over threefold from ₹14.06 crore in the year-a...
Shilpa Medicare shares jump 3% after CDSCO approval for NorUDCA tablets
Shilpa Medicare Limited shares surged by 3% in morning trade following a major announcement from the company. As of 9:18 AM, the shares were trading 3.83% higher at Rs 863.85. The Central Drugs Standa...
Shilpa Medicare gets CDSCO approval for NorUDCA tablets 500 mg, marks first global clearance for NAFLD treatment
Shilpa Medicare Limited has announced that it has received approval from the Central Drugs Standard Control Organization (CDSCO) for its Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg for the treat...
Shilpa Medicare shares jump nearly 5% after USFDA issues EIR with VAI for Bengaluru unit
Shares of Shilpa Medicare Ltd surged nearly 5% on Wednesday, July 16, trading at ₹934.95 on NSE at 10:09 AM — up ₹42.45 from the previous close of ₹892.50 — after the company announced that its Bengal...
Shilpa Medicare subsidiary clears GMP inspection from ANVISA with no major observations
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Pharma Lifesciences Limited (Unit-1), has successfully completed a Good Manufacturing Practice (GMP) inspection conducted by ...
Antique cuts target on Shilpa Medicare to Rs 1,090, retains ‘Buy’ on long-term monetization potential
Antique Broking has maintained a Buy rating on Shilpa Medicare (SLPA) while cutting the target price to ₹1,090 from ₹1,525, citing strong revenue growth in Q4FY25 but tempered expectations for the nea...
Top stocks to watch today, May 27: Lupin, Aurobindo Pharma, NHPC, KEC International, Shilpa Medicare and more
Indian benchmark indices ended higher on Monday, May 26, 2025, supported by positive domestic and global cues. The BSE Sensex gained 455.37 points (0.56%) to close at 82,176.45, while the NSE Nifty50 ...
Shilpa Medicare subsidiary partners with Orion Corporation to commercialize Recombinant Human Albumin in Europe
Shilpa Medicare Limited has announced that its wholly owned subsidiary, Shilpa Biocare Private Limited, has entered into a strategic agreement with Orion Corporation, a pharmaceutical company based in...
Shilpa Medicare shares climb nearly 4% after USFDA EIR for subsidiary, gains European GMP nod for biologics unit
Shares of Shilpa Medicare rose 3.86% to ₹721.75 on the NSE in early trade on Wednesday after the company announced multiple regulatory approvals across its units. The stock opened at ₹701.20 and touch...
Shilpa Medicare’s Bengaluru facility secures GMP approval from EMA for Oral Mouth Dissolving Films and Transdermal Systems
Shilpa Medicare Limited, a leading pharmaceutical company, has announced that its Unit VI facility in Dabaspet, Bengaluru, Karnataka has received Good Manufacturing Practice (GMP) approval from the Eu...
Shilpa Medicare shares jump 3% after arm gets EU GMP clearance for Dharwad plant
Shares of Shilpa Medicare rose 3% in early trade on Monday after its biologics division, Shilpa Biologics, received European GMP certification for its manufacturing site in Dharwad, Karnataka. At 9:40...
Shilpa Medicare settles Celltrion arbitration case with $3.4 million agreement
Shilpa Medicare Limited has entered into a settlement agreement with Celltrion Inc., a South Korea-based pharmaceutical company, thereby resolving an ongoing arbitration dispute. The company informed ...
Shilpa Medicare gets USFDA approval for Varenicline tablets for smoking cessation
Shilpa Medicare Limited, a Raichur-based pharmaceutical company, announced on April 9 that it has received the much-anticipated approval from the U.S. Food and Drug Administration (USFDA) for its Vare...
Shilpa Medicare’s partner Amneal launches BORUZU in US
Shilpa Medicare’s marketing partner, Amneal Pharmaceuticals, has launched BORUZU™ (Bortezomib for Injection, 3.5mg/1.4ml) in the U.S. market. This ready-to-use oncology product is designed for subcuta...
Shilpa Medicare subsidiary signs exclusive deal with Switzerland-based mAbTree Biologics AG
Shilpa Biologicals Pvt Ltd, a subsidiary of Shilpa Medicare Limited, has entered an exclusive co-development and commercialization agreement with Switzerland-based mAbTree Biologics AG for a breakthro...
Shilpa Medicare’s subsidiary clears USFDA inspection with zero observations for second consecutive time
Shilpa Medicare Limited has announced that the United States Food and Drug Administration (USFDA) has successfully completed an inspection at Unit-2 of Shilpa Pharma Lifesciences Limited, a wholly own...
Shilpa Medicare subsidiary receives one observation from USFDA for Unit-1 facility in Raichur
Shilpa Pharma Lifesciences Limited, a wholly owned subsidiary of Shilpa Medicare Limited, successfully completed a United States Food and Drug Administration (USFDA) inspection at its Unit-1 facility ...
Shilpa Medicare secures CDSCO approval for Phase 3 clinical trial
Shilpa Medicare Limited has received approval from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) for its IND – Nor Ursodeoxycholic Acid Tablets 500 mg. ...
Shilpa Medicare Q3 results: Revenue up 11% YoY to Rs 319 crore, Net Profit up 595% YoY
Shilpa Medicare reports Q3 earnings – Key Financial Highlights (Q3 FY25): Net Profit: ₹32 crore, a significant increase compared to ₹4.6 crore in Q3 FY24, marking a strong turnaround. Revenue: ₹319 cr...
Shilpa Medicare subsidiary receives CEP from EDQM for Teriflunomide API
Shilpa Pharma Lifesciences Limited, a wholly-owned subsidiary of Shilpa Medicare Limited, has been awarded the Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines...
Shilpa Medicare secures Portugal marketing authorization for Tadalafil Orodispersible Films
Shilpa Medicare Limited, based in Raichur, Karnataka, has achieved a significant milestone by receiving Marketing Authorization from Portugal for its Tadalafil Orodispersible Films (20 mg). This innov...
Shilpa Medicare receives GMP certification for units IV and VII in Telangana
Shilpa Medicare Ltd. has successfully received Good Manufacturing Practice (GMP) approval from the Ministry of Health, Belarus, for its Unit IV in Jadcherla and Unit VII in Nacharam, Hyderabad. This c...